Dendritic Cell Vaccine for Prostate Cancer from Canada
Autologous dendritic cells loaded with tumor-associated antigens (e.g., Provenge/sipuleucel-T), matured ex vivo for personalized cancer vaccination. HTS 3002.51.00.00 applies to these as cell therapy products—modified cell cultures for active immunotherapy. They prime T-cell responses against prostate cancer cells.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Include antigen pulsing validation and DC maturation markers in shipment docs
• Patient-specific labeling required—match lot to clinical records